Talking Points

C. Michael Gibson and Marco Valgimigli discuss dual antiplatelet therapy after coronary stenting in high-bleeding-risk patients.

C. Michael Gibson, Haibo Jia, and Jingbo Hou discuss whether OCT guidance could cut stent use in STEMI without plaque rupture.

C. Michael Gibson and Douglas Mann discuss sacubitril/valsartan in patients with advanced HFrEF.

C. Michael Gibson and Pavel Osmancik review 3-year results with LAA closure versus a DOAC for patients with atrial fibrillation.

C. Michael Gibson and Pieter C. Smits review outcomes in high-bleeding-risk patients also at high risk for thrombotic events who were randomized to abbreviated DAPT.

C. Michael Gibson discusses aspirin dosing and long-term effectivness with Schuyler Jones and Greg Merritt.

C. Michael Gibson and Kreton Mavromatis discuss how completeness of revascularization impacts quality of life in stable ischemic heart disease patients.

C. Michael Gibson and Steven Nissen discuss the link between omega-3 fatty acid levels and MACE in patients with high cardiovascular risk.

C. Michael Gibson and Robert Galea discuss Amulet versus Watchman for LAA closure.

C. Michael Gibson and Carolyn Lam discuss key updates to the European heart failure guidelines and how best to initiate medications to optimize outcomes.

C. Michael Gibson, Jean-Philippe Collet, and Gilles Montalescot and discuss apixiban after TAVI in the Atlantis trial.

C. Michael Gibson and Firas Zahr discuss 30-day outcomes following transfemoral transseptal TMVR.

C. Michael Gibson and Bruno Scheller discuss 1-year outcomes of two parallel RCTs.

Junjie Zhang and C. Michael Gibson discuss 3-year outcomes after IVUS- versus angiography-guided DES implantation.

Gregg Stone and C. Michael Gibson discuss a randomized trial examining interventional treatment of vulnerable plaques.

Robert Byrne and C. Michael Gibson discuss a randomized trial of a thromboresistant Polyzene F-coated stent with 14-day DAPT in high-bleeding-risk patients.

Otavio Berwanger and C. Michael Gibson discuss rivaroxaban versus warfarin in patients with bioprosthetic mitral valves and atrial fibrillation or flutter.

Corrado Tamburino and C. Michael Gibson discuss a randomized trial of two self-expanding TAVR bioprostheses.

Dean Kereiakes and C. Michael Gibson discuss intravascular lithotripsy for the treatment of severe coronary calcification.

Byeong-Keuk Kim and C. Michael Gibson discuss a randomized trial of ticagrelor monotherapy versus ticagrelor with aspirin in STEMI.